OBJECTIVE: To determine the prevalence and clinical significance of antihistone antibodies (AHA) in systemic sclerosis (SSc). METHODS: Serum samples from patients with limited cutaneous SSc (n = 44), diffuse cutaneous SSc (dcSSc; n = 48), and other SSc-related disorders (n = 22) were examined by enzyme-linked immunosorbent assay and immunoblotting for AHA. RESULTS: AHA were demonstrated in 29% of the 92 SSc patients and in 44% of those with dcSSc. The presence of AHA correlated with severe pulmonary fibrosis in those with dcSSc. Immunoblotting revealed that the predominant antigen was histone H1. CONCLUSION: AHA might be a serologic indicator of the severity of pulmonary fibrosis in SSc.
OBJECTIVE: To determine the prevalence and clinical significance of antihistone antibodies (AHA) in systemic sclerosis (SSc). METHODS: Serum samples from patients with limited cutaneous SSc (n = 44), diffuse cutaneous SSc (dcSSc; n = 48), and other SSc-related disorders (n = 22) were examined by enzyme-linked immunosorbent assay and immunoblotting for AHA. RESULTS: AHA were demonstrated in 29% of the 92 SSc patients and in 44% of those with dcSSc. The presence of AHA correlated with severe pulmonary fibrosis in those with dcSSc. Immunoblotting revealed that the predominant antigen was histone H1. CONCLUSION: AHA might be a serologic indicator of the severity of pulmonary fibrosis in SSc.
Authors: T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth Journal: Ann Rheum Dis Date: 2002-02 Impact factor: 19.103
Authors: B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini Journal: Clin Exp Immunol Date: 2000-09 Impact factor: 4.330
Authors: Adel A Shabana; Atef E El-Ghawet; Shereen A Machaly; Ekbal M Abu Hashim; Basma A El-Kady; Reham Shaat Journal: Clin Rheumatol Date: 2009-03-14 Impact factor: 2.980